(R)-1-phenethyl-N-(1-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

ID: ALA3128227

Chembl Id: CHEMBL3128227

PubChem CID: 76322048

Max Phase: Preclinical

Molecular Formula: C21H21N5

Molecular Weight: 343.43

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  C[C@@H](Nc1ncnc2c1cnn2CCc1ccccc1)c1ccccc1

Standard InChI:  InChI=1S/C21H21N5/c1-16(18-10-6-3-7-11-18)25-20-19-14-24-26(21(19)23-15-22-20)13-12-17-8-4-2-5-9-17/h2-11,14-16H,12-13H2,1H3,(H,22,23,25)/t16-/m1/s1

Standard InChI Key:  JYWCCUAHWOZSAU-MRXNPFEDSA-N

Alternative Forms

1. Parent:

   

   ALA3128227

   N-[(1R)-1-phenylethyl]-1-(2-phenylethyl)pyrazolo[3,4-d]pyrimidin-4-amine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 343.43

Molecular Weight (Monoisotopic): 343.1797

AlogP: 4.24

#Rotatable Bonds: 6

Polar Surface Area: 55.63

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 3.59

CX LogP: 4.09

CX LogD: 4.09

Aromatic Rings: 4

Heavy Atoms: 26

QED Weighted: 0.57

Np Likeness Score: -1.63

References

1. Sartini S, Coviello V, Bruno A, La Pietra V, Marinelli L, Simorini F, Taliani S, Salerno S, Marini AM, Fioravanti A, Orlandi P, Antonelli A, Da Settimo F, Novellino E, Bocci G, La Motta C..  (2014)  Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies.,  57  (4): [PMID:24447248] [10.1021/jm401358b]

Source

Source(1):

• Scientific Literature